• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Pharmaceutical industry reputation recovering

Report: Pharmaceutical industry reputation recovering

May 27, 2016
CenterWatch Staff

The reputation of the pharmaceutical industry is improving in spite of high-profile negative publicity in the past year, according to the 2016 Global Pharma RepTrak released by Reputation Institute.

“The Global Pharma RepTrak shows that pharmaceutical companies’ reputations are improving, and that the overall reputation is average with the general public around the world. However, the industry has much work to do with younger consumers, with whom trust and admiration is much weaker,” said Kasper Ulf Nielsen, executive partner of Reputation Institute. “These results show that the industry is not perceived as badly as many industry insiders think. That should encourage the pharma companies to engage and communicate more, because the general public wants to know more about the companies behind the drugs, and today 44 to 55% are uncertain about what pharma companies do across the seven dimensions of reputation.”

The RepTrak System measures the general public’s perception of the world’s top 14 pharmaceutical companies on the seven key rational dimensions of reputation: products and services, innovation, workplace, governance, citizenship, leadership and performance. It is based on more than 23,000 ratings collected in the first quarter of 2016 from respondents who are at least somewhat familiar with the companies.

The top 10 companies in the 2016 Global Pharma RepTrak are:

  1. Bayer
  2. Abbott Laboratories
  3. Novo Nordisk
  4. Roche
  5. Merck
  6. Sanofi
  7. Allergan
  8. AstraZeneca
  9. Eli Lilly
  10. AbbVie

Bayer rated highest for products and services, financial performance, leadership and workplace, while Novo Nordisk won on the dimensions of innovation, governance and citizenship.

Overall, the industry earned an average RepTrak Pulse score of 67.6, up from 65.7 in 2015. However, the industry reputation is still very polarized, with roughly one-third of respondents viewing the industry as having an excellent reputation, while another third perceive it as weak or poor. An “excellent” reputation is represented by an overall RepTrak Pulse score of 80 or higher. A RepTrak Pulse score of 70 to 79 is considered “strong,” 60 to 69 is “average,” 40 to 59.9 is “weak” and 0 to 39.9 is “poor.”

The industry performs best among older and higher-income consumers, the only demographic to perceive the industry as having a strong reputation overall. The lowest view of the industry comes among consumers aged 18 to 24, who assigned it a RepTrak Pulse rating of 63.4.

Public perceptions of pharmaceutical companies are improving across all seven dimensions of reputation, and for the first time, the industry as a whole returned strong scores for two dimensions: products and services, and financial performance, with scores of 70.2 and 70, respectively. The weakest perceptions are for governance and citizenship, with scores of 66.5 and 65.5, respectively.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing